

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.org) on May 19, 2025

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), APC, eBioscience

RRID:AB_763649

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 17-4714-82, RRID:AB_763649)

Antibody Information

URL: http://antibodyregistry.org/AB_763649

Proper Citation: (Thermo Fisher Scientific Cat# 17-4714-82, RRID:AB_763649)

Target Antigen: Mouse IgG1 kappa

Host Organism: mouse

Clonality: isotype control

Comments: Applications: Flow (Assay-Dependent), Ctrl (Assay-Dependent)
Consolidation on 1/2020: AB_763649, AB_10188110

Antibody Name: Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), APC, eBioscience

Description: This isotype control targets Mouse IgG1 kappa

Target Organism: not applicable

Clone ID: Clone P3.6.2.8.1

Antibody ID: AB_763649

Vendor: Thermo Fisher Scientific

Catalog Number: 17-4714-82

Record Creation Time: 20231110T080026+0000

Record Last Update: 20241115T115837+0000

Ratings and Alerts

No rating or validation information has been found for Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), APC, eBioscience.

No alerts have been found for Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), APC, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 42(6), 985.

Pedde AM, et al. (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. Cell reports, 43(11), 114855.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity, 56(6), 1341.

Pylaeva E, et al. (2022) During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell reports, 40(7), 111171.

Tsuzuki H, et al. (2022) Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. Oncotarget, 13, 1359.

Hong S, et al. (2018) B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity, 49(4), 695.